SHORT-TERM HIGH-DOSE CORTICOSTEROIDS AND GASTRODUODENAL MUCOSA - A PROSPECTIVE CLINICAL-STUDY ON RENAL-TRANSPLANT RECIPIENTS

被引:4
|
作者
PAIMELA, H [1 ]
HOCKERSTEDT, K [1 ]
VONNUMERS, H [1 ]
AHONEN, J [1 ]
机构
[1] HELSINKI UNIV,CENT HOSP,DEPT SURG,SF-00130 HELSINKI 13,FINLAND
关键词
Corticosteroids; gastroduodenal mucosa; Gastroduodenal mucosa; high-dose; high-dose corticosteroids; in kidney transplantation;
D O I
10.1007/BF00336204
中图分类号
R61 [外科手术学];
学科分类号
摘要
In order to evaluate the effect of a short-term high-dose corticosteroid therapy on the gastric and duodenal mucosa, 30 consecutive renal transplant recipients (mean age 39.1 years, 10 women and 20 men) underwent an endoscopic examination of gastroduodenal mucosa 12 and 30 days after renal transplantation. In addition to the postoperative immunosuppressive medication (methylprednisolone and azathioprine), antacids and H2-receptor antagonists were given. Seventeen patients showed no signs of acute rejection, whereas 11 patients experienced one episode and 2 patients two episodes of rejection during endoscopic follow-up. Each rejection episode was treated with a high-dose regimen of methylprednisolone. The two groups of patients studied, i.e., those who did and those who did not experience rejection, were matched for age, sex, period of preoperative dialysis treatment, period of postoperative time elapsed from transplantation, serum creatinine level, and dose of methylprednisolone or azathioprine at the beginning of the endoscopic follow-up, as well as for ulcer prophylactic medication during follow-up. The gastroduodenal mucosa was similar in the two patient groups, both endoscopically and histologically, at the start of the study. During the observation period of 2 weeks, erosive antral gastritis increased significantly in patients who did not experience rejection, whereas in patients with acute rejection and concomitant high-dose corticosteroid therapy, the antral mucosa remained nearly unchanged. Also, the gastric corpus and the duodenum remained unaltered in both groups during follow-up. No ulcer complications occurred in the series. Thus, a high-dose short-term corticosteroid treatment does not seem to be related to grossly harmful side effects in the gastroduodenal mucosa in the immediate post-transplant phase after renal transplantation. This suggests that the current policy of active treatment of renal failure, including antiulcer prophylaxis with H2-receptor antagonists and improved immunosuppressive medication, renders the gastroduodenal mucosa resistant enough to also tolerate the acute post-transplant period well. © 1990 Springer-Verlag.
引用
收藏
页码:62 / 65
页数:4
相关论文
共 50 条
  • [41] Excellent Results of High-Dose Mizoribine Combined With Cyclosporine, Basiliximab, and Corticosteroids in Renal Transplant Recipients-4-Year Results
    Yoshimura, N.
    Ushigome, H.
    Nobori, S.
    Suzuki, T.
    Sakai, K.
    Koshino, K.
    Okajima, H.
    Okamoto, M.
    TRANSPLANTATION PROCEEDINGS, 2013, 45 (04) : 1472 - 1475
  • [42] High-dose immunoglobulin therapy in renal transplant recipients with hemophagocytic histiocytic syndrome
    Asci, Gulay
    Toz, Huseyin
    Ozkahya, Mehmet
    Cagirgan, Seckin
    Duman, Soner
    Sezis, Meltem
    Ok, Ercan
    JOURNAL OF NEPHROLOGY, 2006, 19 (03) : 322 - 326
  • [43] Short-term reduction in bone markers with high-dose simvastatin
    Rosenson, RS
    Tangney, CC
    Langman, CB
    Parker, TS
    Levine, DM
    Gordon, BR
    OSTEOPOROSIS INTERNATIONAL, 2005, 16 (10) : 1272 - 1276
  • [44] Short-term reduction in bone markers with high-dose simvastatin
    Robert S. Rosenson
    Christine C. Tangney
    Craig B. Langman
    Thomas S. Parker
    Daniel M. Levine
    Bruce R. Gordon
    Osteoporosis International, 2005, 16 : 1272 - 1276
  • [45] Short-term reproducibility of total homocysteine determinations in stable renal transplant recipients
    Beaulieu, AJ
    Lapane, KL
    Gohh, RY
    Selhub, J
    Monaco, AP
    Dworkin, L
    Rosenberg, IH
    Bostom, AG
    TRANSPLANTATION PROCEEDINGS, 1999, 31 (05) : 2121 - 2123
  • [46] GANCICLOVIR TREATMENT OF CYTOMEGALOVIRUS INFECTIONS IN RENAL-TRANSPLANT RECIPIENTS - CLINICAL AND PHARMACOKINETIC STUDY
    RONDEAU, E
    FARQUET, C
    FRIES, D
    SRAER, JD
    PRESSE MEDICALE, 1991, 20 (40): : 2030 - 2032
  • [47] PROSPECTIVE-STUDY OF THE HUMAN POLYOMAVIRUSES BK AND JC AND CYTOMEGALOVIRUS IN RENAL-TRANSPLANT RECIPIENTS
    GARDNER, SD
    MACKENZIE, EFD
    SMITH, C
    PORTER, AA
    JOURNAL OF CLINICAL PATHOLOGY, 1984, 37 (05) : 578 - 586
  • [48] THE ROLE OF HYPERTENSION FOR ARTERIAL DISTENSIBILITY IN RENAL-TRANSPLANT RECIPIENTS - A PROSPECTIVE LONGITUDINAL-STUDY
    BARENBROCK, M
    SPIEKER, C
    HOEKS, APG
    ZIDEK, W
    RAHN, KH
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 556 - 556
  • [49] A PROSPECTIVE-STUDY OF LEFT-VENTRICULAR HYPERTROPHY (LVH) IN RENAL-TRANSPLANT RECIPIENTS
    HARNETT, JD
    DEVLIN, WH
    PARFREY, PS
    GRIFFITHS, SM
    GAULT, MH
    GUTTMANN, RD
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1987, 10 (04): : B144 - B144
  • [50] Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction
    Toso, Anna
    Leoncini, Mario
    Maioli, Mauro
    Gallopin, Michela
    Tedeschi, Delio
    Amato, Marcello
    Bellandi, Francesco
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2011, 12 (05) : 318 - 321